Selection of 4 products from
£0.69 to £125.49
Dolagis contain the drug carprofen, which is widely used in veterinary medicine to control pain and inflammation in dogs. It is most often used for osteo-arthritis or degenerative joint disease in older dogs, but can also be used for the treatment of injuries and post-operative discomfort too. Dolagis 50mg tablets and Dolagis 120mg tablets are available. Both sizes are conveniently scored so that they easily break into quarters.
Each Dolagis 50 mg tablet contains Carprofen 50 mg.
Each Dolagis 120 mg chewable tablet contains Carprofen 120 mg
Clover-shaped scored beige tablet. The tablet can be divided into four equal parts.
Reduction of inflammation and pain caused by musculo-skeletal disorders and degenerative joint disease.
As a follow-up to parenteral analgesia in the management of post-operative pain.
Do not use in pregnant and lactating bitches.
Do not use in dogs aged less than 4 months in the absence of specific data.
Do not use in cats.
Do not use in dogs, suffering from cardiac, hepatic or renal disease, when there is a possibility of gastrointestinal ulceration or bleeding or where there is evidence of blood dyscrasia.
Do not use in case of hypersensitivity to the active substance, to other NSAIDs and to any of the excipients.
Use in dogs less than 6 weeks of age, or in aged dogs, may involve additional risk. If such a use cannot be avoided, dogs may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be avoided.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.
As with other NSAIDs, photodermatitis during treatment with carprofen has been observed in laboratory animals and in humans. These skin reactions have never been observed in dogs.
Do not administer other NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.
Due to the good palatability of the tablet, they should be stored in a safe place out of the reach of animals. Intake of dose exceeding the recommended number of tablets may lead to severe adverse effects. If this is the case, seek veterinary assistance immediately.
Typical undesirable effects associated with NSAIDs, such as vomiting, soft faeces/diarrhea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions generally occur within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, use of the product should be stopped and the advice of a veterinarian should be sought.
As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.
Studies in laboratory species (rat and rabbit) have shown evidence of foetotoxic effects of carprofen at doses close to the therapeutic dose. The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Do not use in pregnant or lactating bitches.
For breeding animals, do not use during reproduction period.
Carprofen is highly bound to plasma proteins and compete with other highly bound drugs, which can increase their respective toxic effects.
Do not use this veterinary medicinal drug concurrently with other NSAIDs or with glucocorticoids.
Concurrent administration of potentially nephrotoxic drugs (e.g. aminogylcoside antibiotics) should be avoided.
Amounts to be administered and administration route
For oral administration. 4 mg carprofen per kg bodyweight per day. An initial dose of 4 mg carprofen per kg bodyweight per day given as a single daily dose. The analgesic effect from each dose persists for at least 12 hours. The daily dose may be reduced, subject to clinical response. Duration of treatment will be dependant upon the response seen. Long term treatment should be under regular veterinary supervision. To extend analgesic and anti-inflammatory cover post-operatively parenteral pre-operative treatment with an injectable carprofen may be followed with carprofen tablets at 4 mg/kg/day for 5 days. Do not exceed the stated dose.
The breakability method is the following: Put the tablet on a plain surface, with its scored side facing the surface (convex face up). With the tip of forefinger, exert a slight vertical pressure on the middle of the tablet to break it in its width into halves. In order to obtain quarters, then exert a slight pressure on the middle of one half with forefinger to break it in its length.
The tablet is divisible and flavoured. They are accepted by dogs, but they may be administered directly in the mouth of the dog or added to food if necessary.
Bibliographic data report that carprofen is well tolerated in dogs at twice the recommended dosage for 42 days. Doses up to 3 times the recommended dose are reported to be without adverse effects.
There is no specific antidote to carprofen but general supportive therapy as applied to clinical overdose with NSAIDs should be applied.
Carprofen is a non-steroidal anti-inflammatory drug (NSAID), of the 2-aryl propionic acid class and possesses anti-inflammatory, analgesic and antipyretic activities.
The mechanism of action of carprofen, is not well known. However, it was shown that the inhibition of the cyclo-oxygenase enzyme by carprofen is relatively weak at the recommanded dosage. Moreover, it was shown that carprofen doesn’t inhibit the generation of thromboxane (TX) B2 in dog clotting blood and neither prostaglandin (PG) E2 nor 12-hydroxyeicosatetraenoic acid (HETE) in inflammatory exudate are inhibited. This suggests the mechanism of action of carprofen is not the inhibition of the eicosanoids. Some authors suggested an activity of carprofen on one or numerous inflammatoy mediators not yet identified but no clinical evidence could be shown.
Carprofen exists in two enantiomeric forms, R(-)-carprofen and S(+)-carprofen and the racemic form is the one marketed. Laboratory animal studies suggest that the S(+) enantiomer possesses greater anti-inflammatory potency.
Ulcerogenic potential of carprofen has been shown in the rodents but not in the dogs.
After a single oral administration of 4 mg of carprofen per kg of bodyweight in dog, the time to obtain a maximum plasmatic concentration of 23µg/ml is about 2 hours. The oral bioavailability is more than 90% of the total dose. Carprofen is more than 98% bound to plasma proteins and its volume of distribution is low.
Carprofen is excreted in the bile with 70 % of an intra-venous dose of carprofen being eliminated in the faeces, mainly as the glucuronide conjugate. Carprofen undergoes an enantioselective enterohepatic cycle in dog, with only the S(+) enantiomer being significantly recycled. The plasmatic clearance of the S(+) carprofen is about twice that of the R(-) carprofen. The biliary clearance of S(+) carprofen seems
Pig liver flavour, Yeast, Croscarmellose sodium, Copovidone, Magnesium stearate, Anhydrous colloidal silica, Microcrystalline cellulose, Lactose monohydrate.
Dolagis 50 mg and Dolagis 120 mg: 3 years.
Shelf-life after first opening the immediate packaging: 72 hours
Do not store above 30°C. Protect from light. Divided tablets should be stored in the blister pack. Any divided tablet portions remaining after 72 hours should be discarded.
Dolagis 50 mg Tablet: Blister complex: PVDC-PVC/Aluminium heat sealed blisters with 10 tablets / blister.
Cardboard box with 2 blisters of 10 tablets; Cardboard box with 10 blisters of 10 tablets; Cardboard box with 20 blisters of 10 tablets; Cardboard box with 30 blisters of 10 tablets; Cardboard box with 40 blisters of 10 tablets; Cardboard box with 50 blisters of 10 tablets;
Dolagis 120 mg Chewable Tablet: Blister complex: PVDC-PVC/Aluminium heat sealed blisters with 6 tablets / blister.
Cardboard box with 2 blisters of 6 tablets; Cardboard box with 20 blisters of 6 tablets; Cardboard box with 40 blisters of 6 tablets; Cardboard box with 80 blisters of 6 tablets.
Not all pack sizes may be marketed.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Dolagis 50 mg Tablet for Dogs: Vm 20749/4005.
Dolagis 120 mg Chewable Tablet for Dogs: Vm 20749/4017.
Dolagis 50 mg Tablet for Dogs: 31/01/2008
Dolagis 120 mg Chewable Tablet for Dogs: 4/02/2010.
Dolagis 50 mg Tablet for Dogs: August 2012
Dolagis 120 mg Chewable Tablet for Dogs: August 2011.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: In case of accidental ingestion, seek medical advice immediately and show the package leaflet to the physician. Wash hands after handling the product.
All prices include VAT where applicable. *The freephone number is free from most UK landlines only, mobiles are usually charged so we'd recommend calling our landline from your mobile or internationally.
Below are some recent questions we've received regarding Dolagis Tablets for Dogs, including answers from our team.Ask Your Own Question
Sorry that this product is out of stock, instead of having to keep checking back to see if we have it, we can send you a notification as soon as it comes back in stock.
We won't use any details you enter for any other purpose than letting you know when this is back in stock.
Please enter details for each method you'd like us to notify you by:
VioPoints are a way for us to say thank you for purchasing from VioVet.
You will receive VioPoints by purchasing this product, which can be redeemed for a discount on future purchases. For each 1000 points redeemed at the checkout, you will receive a 20p discount.
The number of VioPoints is shown on the product listing and they are awarded on dispatch of the order.
Terms and conditions apply.